San­doz com­pletes $170M buy of Lu­cen­tis biosim­i­lar from Co­herus Bio­Sciences

San­doz’s $170 mil­lion cash deal to buy oph­thal­mol­o­gy biosim­i­lar Cimer­li from Co­herus Bio­Sciences has com­plet­ed ear­ly fol­low­ing its an­nounce­ment in Jan­u­ary. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA